

Special Issue

Advancing Novel Cancer Therapeutics: Discovery, Validation and Translation of Molecular Targets

Message from the Guest Editors

Despite the availability of surgery, radiation, and chemotherapy, cancer remains a leading cause of mortality worldwide, largely due to the limited selectivity and severe "off-target" side effects of conventional treatments. While precision medicine has introduced monoclonal antibodies and small-molecule inhibitors to target oncoproteins, tumors frequently develop drug resistance, rendering many current therapies ineffective over time. Consequently, there is an urgent need for the discovery, validation, and translation of novel molecular targets that are essential for tumor survival but absent in healthy tissue. This edition of *Cancers* will mainly focus on "Discovery: Identifying the Vulnerability, Validation: Proving the Target and Translation", for example, but not restricted to, "Precision Delivery via Aptamer Conjugates". Also, we would be interested in research highlighting the impact of this drug discovery journey strategically. Any research relevant to precision medicine is also welcome.

Guest Editors

Dr. Chandan Narayan

St. Jude Children's Research Hospital, Memphis, TN, USA

Dr. A. R. M. Ruhul Amin

Department of Pharmaceutical Sciences and Research, Marshall University, Huntington, WV, USA

Deadline for manuscript submissions

31 October 2026



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 9.0
Indexed in PubMed



mdpi.com/si/278012

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 9.0
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)